We make finished medicines in every major form, by the billion.
Polpharma Group turns its own active substances and formulations into the finished medicine, on five specialised plants producing at the scale a region's supply depends on.
TABLETS A YEAR
5.2B
CAPSULES A YEAR
700M
AMPOULES A YEAR
185M
PLANTS ACROSS CEE & CAC
7
SKUS IN SALES
2,000+
REVENUE MADE IN-HOUSE
75%
Forms few European plants can manufacture.
Beyond the standard oral range, the Group operates the specialty platforms most generic manufacturers contract out - certified and at commercial scale.
Blow-Fill-Seal Parenterals
Cephalosporin Antibiotics
Co-Integrated Inhalers
Complex Sterile Injectables
High-Potent Solids
Long-Acting Injectables
Preservative-Free Ophthalmics
Soft Gelatin Capsules
Group’s commentary
The formulation, device and synthesis work behind these programmes runs at the Group's R&D centres.
The Manufacturing Network
An integrated manufacturing platform, built for reliability of supply.
Solid oral forms & sterile parenterals at scale
High-potent & high-containment solid forms
Soft-gel capsules, non-sterile liquids & DPI
Cephalosporin antibiotics, sterile & oral
Parenterals & sterile antibiotics for Central Asia
Pharma & cosmetic forms across all formats
Ophthalmic packaging & dosing components
500+ products and 2000+ SKUs across the therapeutic spectrum.
Our portfolio covers prescription and over-the-counter products for our key therapy areas, as well as medicines and healthcare solutions developed in collaboration with business partners. Our catalogue comprises 500 products, and our plants produce approximately 400 million packs a year.
Portfolio Information
Detailed portfolio information, product registrations and market-specific availability are provided through approved business channels and in accordance with applicable regulatory and confidentiality requirements.
PARTNERSHIP models
The Group's own FDF platform is open to your product.
FDF Manufacturing
FDF CMO
FDF Co-development
Technology transfer
FROM TRANSFER TO SUPPLY
A product moves from tech transfer to full-rate supply on lines already in daily production.
A transfer-in or a new build follows the same staged route the Group uses to bring up its own launches - assessed, validated, registered and scaled, each gate signed off before the next opens.
Regulatory & Quality
EU GMP at every plant, with the certification each market requires.
Polpharma operates a single Quality Management System across all manufacturing sites, ensuring consistent standards and continuous improvement throughout the organization.
Track record at a glance
Quality
EU GMP-certified
plants
Regulatory inspections
performed annually by authorities
Customer audits
hosted each year
Internal audits
conducted annually on average
Filed and maintained against every framework where the developed portfolio ships.
Regulatory
We have successfully undergone numerous regulatory inspections and audits conducted by health authorities and certification bodies worldwide, including the Eurasian Economic Union (EAEU), the Saudi Food and Drug Authority (SFDA), the Ukrainian authority, and TÜV NORD for Medical Devices.
Drug security index
Through the pandemic and the 2022 European energy crisis, supply held without interruption. The Group is the only manufacturer in Poland of 42 medicinal products, several of them life-saving, and holds a drug-security index of 92 percent across the Polish operations.
how we work with you
One operating standard, run by the people you actually talk to.
Working with Polpharma Group means partnering with teams that combine manufacturing expertise, quality-focused execution and a structured approach to operational excellence.
We manage the activities required to bring finished pharmaceutical products to patients, from production and packaging through quality oversight and market-specific requirements, while maintaining consistent standards across the manufacturing network.
Reliable
supply planning
Production schedules are managed through established planning processes designed to support continuity, flexibility and long-term cooperation with our partners.
Market-ready
packaging solutions
Packaging materials and product information are prepared in accordance with applicable regulatory requirements and adapted to the needs of individual markets.
Compliance
and traceability
Products are manufactured, packed and distributed within defined quality systems and in accordance with applicable regulatory and traceability requirements.
Coordinated
lifecycle management
Changes affecting products, materials or processes are managed through structured cross-functional collaboration to help ensure alignment between manufacturing, quality and regulatory requirements.
"To remain competitive in both domestic and international markets, we need to be flexible and maintain precise control over our processes. Harmonised processes across the organisation, reduced time spent on reporting and data administration, and the ability to respond immediately to process deviations all support this.
Dorota Chęć Supply Chain Management Head
WHY US
We build our business around long-term partner supply.
Primarily, Polpharma Group runs manufacturing network to produce own product portfolio to maximize value chain. The same lines, quality system and supply discipline are open to partners bringing a product to manufacture or a process to move in.
20%+ of Group revenue from partnerships
Partner work already brings in more than a fifth of Group revenue, so a partner's programme sits inside the core business, with the attention that carries.
100+ partners sourcing from the Group
More than a hundred companies worldwide source products from the Group, across FDF supply, technology transfer and long-term manufacturing.
60+ partnership deals closed a year
Over sixty partnership deals close in a typical year, a cadence that comes from doing this routinely rather than opportunistically.